ClinEdge Offering Complimentary Patient Services to Organizations Developing Compounds for the Coronavirus

ClinEdge is offering several of its comprehensive patient services free of charge to any pharmaceutical and biotech companies conducting clinical vaccine trials for the coronavirus.

BOSTON--(BUSINESS WIRE)--ClinEdge, a Boston-based clinical trial solutions provider is offering several of its product lines as complimentary support to any sponsor organization launching urgent human clinical trials related to coronavirus compounds (also known as COVID-19).

Two months after China reported the first case of the illness caused by the novel coronavirus, new infections continue emerging in other parts of the world. As the epidemic advances and containment strategies seem to fail, countries prepare for the possibility of a pandemic. Developing a cure is now of critical importance.

“COVID-19 presents a severe global problem and we want to encourage and support pharmaceutical vaccine development for coronavirus in any way we can,” said Christian Burns, President at ClinEdge. ”We have supported vaccine development in the past but, now more than ever, pharmaceutical and biotech companies need support to receive this urgently needed vaccine approval, and the best way we can help is by offering our patient recruitment and retention services at no cost.”

With the growing global epidemic, ClinEdge says it is prepared to support any researcher, pharmaceutical, or biotech company developing a vaccine against coronavirus or COVID-19. However, the World Health Organization and world leaders have warned that false information about the coronavirus threatens to cause what has been labeled an “infodemic.” Consequently, providing patient and caregiver education for a new vaccine to healthy and virus-infected patients will present new challenges. Burns says ClinEdge has the experience to overcome them.

“With our extensive experience across dozens of vaccines and acute infectious disease studies, we have a variety of tools and resources that could help sponsors accelerate clinical development in human clinical trials, enabling a quicker vaccine approval,” Burns concluded.

For more information on ClinEdge and this complimentary service offering visit www.Clin-Edge.com.

About ClinEdge
ClinEdge, a portfolio company of ClinX, provides a full suite of clinical and outsourced business services to clinical research institutions, pharmaceutical companies, and CRO’s. The company includes a global site network of research clinics, marketing and creative design services, patient recruitment, and patient travel services. With extensive experience in medical indications representing most therapeutic areas, the company has helped clients successfully conduct thousands of clinical studies by, maximizing clinical research operations, minimizing enrollment times, and improving overall business performance. To learn more about ClinEdge visit www.Clin-Edge.com.